Home LiteratureArticle Details
PMID: 11189684 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Controlled clinical trials ·Vol. 21 ·No. 6 Suppl ·2000-12-00 ·Pages 273S-309S

Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team

Abstract

The objectives of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial are to determine in screenees ages 55-74 at entry whether screening with flexible sigmoidoscopy (60-cm sigmoidoscope) can reduce mortality from colorectal cancer, whether screening with chest X-ray can reduce mortality from lung cancer, whether screening men with digital rectal examination (DRE) plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer, and whether screening women with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer. Secondary objectives are to assess screening variables other than mortality for each of the interventions including sensitivity, specificity, and positive predictive value; to assess incidence, stage, and survival of cancer cases; and to investigate biologic and/or prognostic characterizations of tumor tissue and biochemical products as intermediate endpoints. The design is a multicenter, two-armed, randomized trial with 37,000 females and 37,000 males in each of the two arms. In the intervention arm, the PSA and CA125 tests are performed at entry, then annually for 5 years. The DRE, TVU, and chest X-ray exams are performed at entry and then annually for 3 years. Sigmoidoscopy is performed at entry and then at the 5-year point. Participants in the control arm follow their usual medical care practices. Participants will be followed for at least 13 years from randomization to ascertain all cancers of the prostate, lung, colorectum, and ovary, as well as deaths from all causes. A pilot phase was undertaken to assess the randomization, screening, and data collection procedures of the trial and to estimate design parameters such as compliance and contamination levels. This paper describes eligibility, consent, and other design features of the trial, randomization and screening procedures, and an outline of the follow-up procedures. Sample-size calculations are reported, and a data analysis plan is presented.

MeSH Terms
Colorectal Neoplasms/diagnosis,prevention & control Female Humans Lung Neoplasms/diagnosis,prevention & control Male Mass Screening Multicenter Studies as Topic Ovarian Neoplasms/diagnosis,prevention & control Prostatic Neoplasms/diagnosis,prevention & control Randomized Controlled Trials as Topic Research Design
Authors & Affiliations
23 authors, click to expand affiliations / ORCID
Prorok P C
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892-7346, USA.
Andriole G L
Bresalier R S
Buys S S
Chia D
Crawford E D
Fogel R
Gelmann E P
Gilbert F
Hasson M A
Hayes R B
Johnson C C
Mandel J S
Oberman A
O'Brien B
Oken M M
Rafla S
Reding D
Rutt W
Weissfeld J L
Yokochi L
Gohagan J K
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team
Article Info
Journal
Controlled clinical trials
Abbr.
Control Clin Trials
ISSN
0197-2456
Published
2000-12-00
Pages
273S-309S
Language
English
Region
United States
NLM ID
8006242
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]